Balaji Gandhi Sells 5,771 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) CFO Balaji Gandhi sold 5,771 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $30.04, for a total transaction of $173,360.84. Following the sale, the chief financial officer now directly owns 105,514 shares in the company, valued at $3,169,640.56. This trade represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The stock was sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total transaction of $85,018.95.

Phreesia Trading Down 3.8 %

NYSE PHR traded down $1.07 during trading hours on Monday, reaching $27.15. The company's stock had a trading volume of 399,788 shares, compared to its average volume of 386,314. The firm has a fifty day simple moving average of $27.32 and a 200-day simple moving average of $23.90. The stock has a market cap of $1.58 billion, a P/E ratio of -18.47 and a beta of 0.96. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm's quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.58) EPS. Equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. PharVision Advisers LLC bought a new position in Phreesia in the 4th quarter valued at approximately $302,000. Two Sigma Advisers LP bought a new position in Phreesia during the 4th quarter worth approximately $302,000. Silvercrest Asset Management Group LLC raised its holdings in Phreesia by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company's stock worth $9,922,000 after purchasing an additional 93,349 shares during the last quarter. ProShare Advisors LLC raised its holdings in Phreesia by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 15,585 shares of the company's stock worth $392,000 after purchasing an additional 5,127 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Phreesia by 77.1% during the 4th quarter. Nuveen Asset Management LLC now owns 235,827 shares of the company's stock worth $5,933,000 after purchasing an additional 102,662 shares during the last quarter. Institutional investors own 92.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PHR shares. Citigroup increased their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. KeyCorp increased their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 8th. Royal Bank of Canada upgraded shares of Phreesia from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Truist Financial increased their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Finally, Piper Sandler restated an "overweight" rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.